阵发性夜间血红蛋白尿中依库珠单抗血液学反应的分类：一项多中心真实世界研究 - Suppr

Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.

作者信息

Debureaux Pierre-Edouard, Kulasekararaj Austin G, Cacace Fabiana, Silva Bruno G P, Calado Rodrigo T, Barone Federica, Sicre de Fontbrune Flore, Prata Pedro Henrique, Soret Juliette, Sica Michela, Notaro Rosario, Scheinberg Phillip, Mallikarjuna Vasundhara, Gandhi Shreyans, Large Joanna, Risitano Antonio M, Peffault de Latour Regis, Frieri Camilla

机构信息

French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Saint-Louis hospital, Paris, France.

Department of Hematological Medicine, King's College Hospital, National Institute of Health Research/Welcome King's Clinical Research Facility and King's College London, London, United Kingdom.

出版信息

Bone Marrow Transplant. 2021 Oct;56(10):2600-2602. doi: 10.1038/s41409-021-01372-0. Epub 2021 Jul 5.

DOI:10.1038/s41409-021-01372-0

PMID:34226670

Abstract

摘要

相似文献

Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.

Bone Marrow Transplant. 2021 Oct;56(10):2600-2602. doi: 10.1038/s41409-021-01372-0. Epub 2021 Jul 5.

Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.

BioDrugs. 2012 Apr 1;26(2):125-30. doi: 10.2165/11208420-000000000-00000.

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.

Cochrane Database Syst Rev. 2014 Oct 30(10):CD010340. doi: 10.1002/14651858.CD010340.pub2.

Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.

Expert Rev Hematol. 2009 Feb;2(1):7-16. doi: 10.1586/17474086.2.1.7.

[Rare case of a pregnancy in a woman with paroxysmal nocturnal hemoglobinuria. Case report].

Orv Hetil. 2016 Jun 5;157(23):916-8; quiz 919-20. doi: 10.1556/650.2016.30430.

Eculizumab in paroxysmal nocturnal hemoglobinuria.

N Engl J Med. 2006 Dec 28;355(26):2787; author reply 2787-8.

Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.

Pharmacoeconomics. 2020 Sep;38(9):981-994. doi: 10.1007/s40273-020-00929-z.

[Evidence of the efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria].

Rev Med Suisse. 2006 Oct 4;2(81):2255.

Paroxysmal nocturnal hemoglobinuria and eculizumab.

Haematologica. 2010 Apr;95(4):523-6. doi: 10.3324/haematol.2009.017848.

Utility of dynamic contrast-enhanced MRI to assess small bowel perfusion in paroxysmal nocturnal hemoglobinuria before and after eculizumab.

Eur J Intern Med. 2018 Nov;57:e25-e27. doi: 10.1016/j.ejim.2018.08.005. Epub 2018 Aug 17.

引用本文的文献

Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor-Naive Patients With Paroxysmal Nocturnal Haemoglobinuria.

EJHaem. 2025 May 20;6(3):e270055. doi: 10.1002/jha2.70055. eCollection 2025 Jun.

Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.

Blood Adv. 2025 Apr 22;9(8):1816-1826. doi: 10.1182/bloodadvances.2024014652.

[Interpretation of the guidelines for diagnosing and treating paroxysmal nocturnal hemoglobinuria in China (2024)].

Zhonghua Xue Ye Xue Za Zhi. 2024 Dec 14;45(12):1071-1077. doi: 10.3760/cma.j.issn.0253-2727.2024.12.101.

Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment.

Transfus Med Hemother. 2024 Aug 21;51(5):310-320. doi: 10.1159/000540474. eCollection 2024 Oct.

Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations.

J Blood Med. 2023 Dec 6;14:613-628. doi: 10.2147/JBM.S431493. eCollection 2023.

Complement in human disease: approved and up-and-coming therapeutics.

Lancet. 2024 Jan 27;403(10424):392-405. doi: 10.1016/S0140-6736(23)01524-6. Epub 2023 Nov 15.

Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment.

Hematol Rep. 2023 Oct 13;15(4):578-591. doi: 10.3390/hematolrep15040060.

Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network.

Hematol Rep. 2023 Apr 21;15(2):266-282. doi: 10.3390/hematolrep15020027.

Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.

Blood Adv. 2023 Jun 13;7(11):2468-2478. doi: 10.1182/bloodadvances.2022009129.

Clin Case Rep. 2023 Feb 8;11(2):e6835. doi: 10.1002/ccr3.6835. eCollection 2023 Feb.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.

作者信息

机构信息

French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Saint-Louis hospital, Paris, France.

Department of Hematological Medicine, King's College Hospital, National Institute of Health Research/Welcome King's Clinical Research Facility and King's College London, London, United Kingdom.

出版信息

Bone Marrow Transplant. 2021 Oct;56(10):2600-2602. doi: 10.1038/s41409-021-01372-0. Epub 2021 Jul 5.

DOI:10.1038/s41409-021-01372-0

PMID:34226670

Abstract

摘要

相似文献

Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.

Bone Marrow Transplant. 2021 Oct;56(10):2600-2602. doi: 10.1038/s41409-021-01372-0. Epub 2021 Jul 5.

Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.

BioDrugs. 2012 Apr 1;26(2):125-30. doi: 10.2165/11208420-000000000-00000.

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.

Cochrane Database Syst Rev. 2014 Oct 30(10):CD010340. doi: 10.1002/14651858.CD010340.pub2.

Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.

Expert Rev Hematol. 2009 Feb;2(1):7-16. doi: 10.1586/17474086.2.1.7.

[Rare case of a pregnancy in a woman with paroxysmal nocturnal hemoglobinuria. Case report].

Orv Hetil. 2016 Jun 5;157(23):916-8; quiz 919-20. doi: 10.1556/650.2016.30430.

Eculizumab in paroxysmal nocturnal hemoglobinuria.

N Engl J Med. 2006 Dec 28;355(26):2787; author reply 2787-8.

Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.

Pharmacoeconomics. 2020 Sep;38(9):981-994. doi: 10.1007/s40273-020-00929-z.

[Evidence of the efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria].

Rev Med Suisse. 2006 Oct 4;2(81):2255.

Paroxysmal nocturnal hemoglobinuria and eculizumab.

Haematologica. 2010 Apr;95(4):523-6. doi: 10.3324/haematol.2009.017848.

Utility of dynamic contrast-enhanced MRI to assess small bowel perfusion in paroxysmal nocturnal hemoglobinuria before and after eculizumab.

Eur J Intern Med. 2018 Nov;57:e25-e27. doi: 10.1016/j.ejim.2018.08.005. Epub 2018 Aug 17.

引用本文的文献

Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor-Naive Patients With Paroxysmal Nocturnal Haemoglobinuria.

EJHaem. 2025 May 20;6(3):e270055. doi: 10.1002/jha2.70055. eCollection 2025 Jun.

Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.

Blood Adv. 2025 Apr 22;9(8):1816-1826. doi: 10.1182/bloodadvances.2024014652.

[Interpretation of the guidelines for diagnosing and treating paroxysmal nocturnal hemoglobinuria in China (2024)].

Zhonghua Xue Ye Xue Za Zhi. 2024 Dec 14;45(12):1071-1077. doi: 10.3760/cma.j.issn.0253-2727.2024.12.101.

Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment.

Transfus Med Hemother. 2024 Aug 21;51(5):310-320. doi: 10.1159/000540474. eCollection 2024 Oct.

Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations.

J Blood Med. 2023 Dec 6;14:613-628. doi: 10.2147/JBM.S431493. eCollection 2023.

Complement in human disease: approved and up-and-coming therapeutics.

Lancet. 2024 Jan 27;403(10424):392-405. doi: 10.1016/S0140-6736(23)01524-6. Epub 2023 Nov 15.

Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment.

Hematol Rep. 2023 Oct 13;15(4):578-591. doi: 10.3390/hematolrep15040060.

Hematol Rep. 2023 Apr 21;15(2):266-282. doi: 10.3390/hematolrep15020027.

Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.

Blood Adv. 2023 Jun 13;7(11):2468-2478. doi: 10.1182/bloodadvances.2022009129.

Clin Case Rep. 2023 Feb 8;11(2):e6835. doi: 10.1002/ccr3.6835. eCollection 2023 Feb.

Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献